Skip to main content
Premium Trial:

Request an Annual Quote

T2 Biosystems T2Resistance Panel

The T2 Biosystems T2Resistance Panel for genotypic antibiotic resistance marker testing is now available as a research use only test in the US. The panel uses the firm's T2Dx instrument and identifies 13 genes conferring resistance to common empiric antibiotic therapies, such as carbapenems, vancomycin, and penicillin, directly from whole blood within three to five hours. The panel received breakthrough device designation from the US Food and Drug Administration earlier this year and is on track to receive CE mark by the end of 2019.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.